ASX - By Stock
|
MSB |
Re:
Valuation
|
|
nosluggos
|
77 |
37K |
2 |
10:04 |
10:04 |
ASX - By Stock
|
77
|
37K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
ASX Hot too!
|
|
nosluggos
|
296 |
86K |
3 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
296
|
86K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
ASX Hot too!
|
|
nosluggos
|
296 |
86K |
6 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
296
|
86K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
nosluggos
|
77 |
37K |
38 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
77
|
37K
|
38
|
|
Charts
|
MSB |
Re:
chart
|
|
nosluggos
|
31 |
13K |
5 |
17/04/24 |
17/04/24 |
Charts
|
31
|
13K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Morningstar, Fair value for MSB Shareprice: $2.23/s
|
|
nosluggos
|
11 |
5.0K |
0 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
11
|
5.0K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Morningstar, Fair value for MSB Shareprice: $2.23/s
|
|
nosluggos
|
11 |
5.0K |
0 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
11
|
5.0K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Morningstar, Fair value for MSB Shareprice: $2.23/s
|
|
nosluggos
|
11 |
5.0K |
40 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
11
|
5.0K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
nosluggos
|
5.1K |
2.5M |
9 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
5.1K
|
2.5M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
nosluggos
|
554 |
221K |
1 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
554
|
221K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
nosluggos
|
554 |
221K |
0 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
554
|
221K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
nosluggos
|
1.3K |
545K |
6 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
1.3K
|
545K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
nosluggos
|
1.3K |
545K |
45 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
1.3K
|
545K
|
45
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
nosluggos
|
275 |
110K |
13 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
275
|
110K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
nosluggos
|
1.0K |
384K |
13 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
384K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DREAM HF Trial Published in JACC
|
|
nosluggos
|
111 |
40K |
33 |
02/03/23 |
02/03/23 |
ASX - By Stock
|
111
|
40K
|
33
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
nosluggos
|
17K |
6.6M |
30 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
17K
|
6.6M
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
nosluggos
|
17K |
6.6M |
4 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
17K
|
6.6M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Director Appointment
|
|
nosluggos
|
213 |
58K |
13 |
24/03/22 |
24/03/22 |
ASX - By Stock
|
213
|
58K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Short Squeeze
|
|
nosluggos
|
505 |
160K |
15 |
10/03/22 |
10/03/22 |
ASX - By Stock
|
505
|
160K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Novartis Agreement
|
|
nosluggos
|
850 |
250K |
13 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
850
|
250K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: CEO Presentation to 2021 Annual General Meeting
|
|
nosluggos
|
54 |
17K |
8 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
54
|
17K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Q1 Financial Results and Operational Highlights
|
|
nosluggos
|
124 |
38K |
4 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
124
|
38K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Q1 Financial Results and Operational Highlights
|
|
nosluggos
|
124 |
38K |
12 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
124
|
38K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
10 days until shorters shower in resplendent glory and profit more
|
|
nosluggos
|
23 |
6.4K |
3 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
23
|
6.4K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
nosluggos
|
173 |
46K |
5 |
31/10/21 |
31/10/21 |
ASX - By Stock
|
173
|
46K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
nosluggos
|
173 |
46K |
5 |
31/10/21 |
31/10/21 |
ASX - By Stock
|
173
|
46K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
nosluggos
|
13K |
4.9M |
19 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
nosluggos
|
192 |
86K |
48 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
192
|
86K
|
48
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
nosluggos
|
1.0K |
416K |
22 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
416K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
nosluggos
|
1.0K |
416K |
29 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
416K
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
nosluggos
|
1.0K |
416K |
28 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
416K
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
nosluggos
|
811 |
332K |
2 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
332K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
nosluggos
|
811 |
332K |
40 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
332K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
nosluggos
|
13K |
4.9M |
4 |
18/11/20 |
18/11/20 |
ASX - By Stock
|
13K
|
4.9M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
nosluggos
|
13K |
4.9M |
44 |
18/11/20 |
18/11/20 |
ASX - By Stock
|
13K
|
4.9M
|
44
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
nosluggos
|
445 |
193K |
2 |
15/10/20 |
15/10/20 |
ASX - By Stock
|
445
|
193K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
nosluggos
|
13K |
4.9M |
11 |
07/10/20 |
07/10/20 |
ASX - By Stock
|
13K
|
4.9M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
MSB to dispute FDA finding in Type A meeting
|
|
nosluggos
|
1.0K |
501K |
19 |
04/10/20 |
04/10/20 |
ASX - By Stock
|
1.0K
|
501K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
nosluggos
|
13K |
4.9M |
21 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
13K
|
4.9M
|
21
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
nosluggos
|
13K |
4.9M |
20 |
28/09/20 |
28/09/20 |
ASX - By Stock
|
13K
|
4.9M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
nosluggos
|
576 |
230K |
2 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
576
|
230K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
nosluggos
|
576 |
230K |
8 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
576
|
230K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
nosluggos
|
576 |
230K |
10 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
576
|
230K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Annual Financial Results Presentation
|
|
nosluggos
|
97 |
42K |
32 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
97
|
42K
|
32
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Annual Financial Results Presentation
|
|
nosluggos
|
97 |
42K |
40 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
97
|
42K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
nosluggos
|
576 |
230K |
14 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
230K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
nosluggos
|
576 |
230K |
31 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
230K
|
31
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - Most exciting 6 months
|
|
nosluggos
|
729 |
370K |
1 |
24/08/20 |
24/08/20 |
ASX - By Stock
|
729
|
370K
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - Most exciting 6 months
|
|
nosluggos
|
729 |
370K |
4 |
24/08/20 |
24/08/20 |
ASX - By Stock
|
729
|
370K
|
4
|
|